Objective: To evaluate demographics and outcomes of maternal-fetal pairs in early onset fetal growth restriction (FGR) requiring delivery prior to 34 weeks’ gestation based on ultrasound indication leading to diagnosis. Study Design: This is a descriptive study of maternal-fetal pairs with early FGR diagnosed prior to 30 weeks’ gestation and delivering between 22w0d and 34w0d under the care of Wake Forest University Perinatology 01/2012-12/2016. 

Diagnosis is a process that identifies, explains, or establishes the individual’s disease from its symptoms and signs. Early and precise diagnosis is crucial since it influences the efficacy of treatment and avoids longterm complications for the infected person. Further, in the case of infectious diseases, undiagnosed patients can transmit the disease to a healthy population unknowingly. Besides, most of the diseases evolve with the time that significantly affects the clinical outcomes.

Despite the curious advancement in medical science and therapeutics, tuberculosis (TB) persist the primary factor of mortality than any other infectious disease and socioeconomic disaster for millions of people around the world. According to the World Health Organization (WHO), World’s One-third of the population is infected with this disease and of these, 8 to 10 million people develop active disease and 2 million people die each year and the rest of the infected people remain asymptomatic.

Insulinomas are insulin secreting tumors arising from spontaneous mutations of the ductal, acinar, or islet cells of the pancreas. They are rare, having an incidence of only four cases per million people per year. Patients typically present with fasting hypoglycemia, experiencing neurologic symptoms like confusion, changes in vision, or abnormal behavior and autonomic symptoms like palpitations, diaphoresis, or tremulousness.

Immune checkpoint inhibitor (ICI)-associated cardiotoxicity is a rare immune-related adverse event with high mortality. In recent years, more and more reports were reported. It is urgent to improve understanding and management. Cardiac toxicity often occurs in the early stage after ICI treatment, and its clinical manifestations are diverse and nonspecific, and its pathogenesis is still unclear. Among them, the incidence of immune myocarditis is more than 1%, which can be manifested as fulminant, acute or chronic.